Fulcrum Therapeutics prices $175M upsized public offering of common stock and pre-funded warrants

Fulcrum Therapeutics, Inc.

Priced underwritten offering of 11,851,853 shares at $13.50/share and pre-funded warrants for 1,111,193 shares at $13.499 each.
Gross proceeds of $175M; net proceeds estimated at $164.1M (or $188.1M if underwriter option exercised).
Offering upsized; underwriters granted 30-day option to purchase up to 1,944,456 additional shares.
Net proceeds to fund general corporate purposes, including R&D, clinical trials, and potential acquisitions.
Closing expected on or about December 11, 2025, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Fulcrum Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co. (effective 2025-12-10).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co.
Effective: 2025-12-10

Exact text from the filing

On December 10, 2025, Fulcrum Therapeutics, Inc., or Fulcrum, entered into an underwriting agreement, or the Underwriting Agreement, with J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co., as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering

View on SEC.gov

Browse all material agreements →

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-314728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.